A new position statement from the American Academy of Sleep Medicine suggests clinicians should prioritize the evaluation and ...

Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment. Jazz Pharmaceuticals markets multiple ...

Avadel Pharmaceuticals (AVDL) and nference announced the publication of real-world data on comorbidities and treatment patterns of people with ...

NGENū CRO, a specialist Contract Research Organization with deep expertise in the complex field of sleep medicine, is pleased ...

Narcolepsy is linked to adverse cardiovascular disease (CVD) outcomes, but few studies have examined its associations with subclinical CVD, including in children. We assessed the relationship between ...

Specifically: In Q1 2025 patient demand metrics for LUMRYZ™, Avadel’s innovative narcolepsy medication ... 3 pivotal trial studying LUMRYZ in Idiopathic Hypersomnia (IH), is on track to ...

Xyrem, a medication approved in the U.S., is used for the treatment of excessive daytime sleepiness and sudden loss of muscle control in patients suffering from narcolepsy, a chronic neurological ...

Centessa has two orexin agonists, ORX750 for the treatment of sleep-wake disorders, including NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), and ORX142 for the treatment of EDS in ...

Secondary endpoints of the Vibrance-3 study are changes in the Idiopathic Hypersomnia Severity Scale ... also being developed for the treatment of narcolepsy type 1 and type 2.

Last year, Alkermes announced positive topline data from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a Phase Ib trial of ALKS 2680. Give your business an edge with our ...